AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021 -- 1 of 81 -- 2 Discovery Insure Discovery Life Discovery Invest Discovery Bank Discovery Health Vitality Health Vitality Car Vitality Life Vitality Invest Global Network USA +9% core new business API, i.e. excluding DH take-on of new closed schemes and gross revenue for Vitality Group New business +11% to R22 595m Normalised operating profit +7% to R6 494m Normalised headline earnings -9% to R3 406m Headline earnings +12% to R3 711m Life COVID-19 provisions R2.8bn NHE before forex impact +909% to R2 986m -- 2 of 81 -- 3 The period under review Resilient performance with operating profit up 7%, new business up 11% and actuarial dynamics in line with expectation Navigating the significant impact of COVID-19; meeting our core purpose and serving society by ensuring quick and efficient vaccination of all South Africans A pivot to growth by capitalising on the applicability of the Vitality Shared-value model to ensure: a) Organic growth b) Geographic growth c) Platform-led growth 1 Navigating COVID-19 2 Resilient operating performance 3 Capital strength and liquidity 4 Three dimensions of growth Capital strength and liquidity remained a key focus - all metrics above target and with sufficient buffers Require capital for Ping An Health to support business growth and product diversification -- 3 of 81 -- Navigating COVID-19 and meeting our core purpose 1 -- 4 of 81 -- 5 Our strategic response to the pandemic Maintain financial strength and resilience Support our country Protect our people Protect and support our clients Employee vaccine mandate Structural and pricing changes to products Central role in state-led COVID-19 response Implement mandatory vaccination policy from 1 January 2022 DSY offices and sites become vaccination-only zones Preferred premiums for vaccinated DL members Product incentives to vaccinate R2 800m Life provisions across the Group R2 448m DL earnings impact for period under review 9 DH vaccination sites 1 000 staff deployed >550 000 vaccinations administered - c5% of total national vaccinations cR200m allocated to campaign (R42m in this period) -- 5 of 81 -- 6 COVID-19 in South Africa was worse than predicted Deaths (90% excess deaths) DSY predicted the first wave well 87k Discovery medium 48k ASSA Scenario 1 50k Government model 12k PANDA 76k Actual deaths (90% Excess deaths) - 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 Orig. Beta Delta Infectious variant coincided with holiday season CFR for Beta variant higher Delay in vaccination programme Higher proportion of infections in younger age groups Initial predicted deaths to Dec 20, at May 2020 DSY underestimated the peak of Wave 2 and the timing and extent of Wave 3 90% excess deaths DSY prediction for current FY -- 6 of 81 -- 7 SA’s epidemic was 5x worse than the UK’s - 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 - 20,000 40,000 60,000 80,000 100,000 120,000 140,000 160,000 20200503 20200517 20200531 20200614 20200628 20200712 20200726 20200809 20200823 20200906 20200920 20201004 20201018 20201101 20201115 20201129 20201213 20201227 20210110 20210124 20210207 20210221 20210307 20210321 20210404 20210418 20210502 20210516 20210530 20210613 20210627 20210711 20210725 20210808 Infections Deaths - 1,000 2,000 3,000 4,000 5,000 6,000 7,000 8,000 9,000 - 50,000 100,000 150,000 200,000 250,000 300,000 350,000 400,000 450,000 20200503 20200517 20200531 20200614 20200628 20200712 20200726 20200809 20200823 20200906 20200920 20201004 20201018 20201101 20201115 20201129 20201213 20201227 20210110 20210124 20210207 20210221 20210307 20210321 20210404 20210418 20210502 20210516 20210530 20210613 20210627 20210711 20210725 20210808 Infections Deaths New cases Deaths (90% excess) New cases Deaths IFR Deaths (90% excess) Implied infections Population % population infected 0.39% - 0.5% 215k 45m 60m 70% - 80% IFR Deaths (90% excess) Implied infections Population % population infected 1.09% 132k 12m 68m 18% Given SA’s younger age profile, expect deaths to be 64% lower, but when adjusting for population size (12% smaller) the data indicates epidemic currently 5.5x worse than UK Vaccinations decouple infections and deaths -- 7 of 81 -- 8 Factors that influence COVID-19 waves COVID Wave = (1-Immunity) P(contact) x Risk index x Population immunity Reinfection rates Vaccines 70%-80% of the population infected 20%-25% of the population re-infected 24% of the population vaccinated Behaviour COVID-19 variants Community prevalence Resilience index New variants Risk of (re)infection At least 40% of the population are still vulnerable to new or reinfection 1 Reduced vulnerability Vaccinated and previously infected people have far higher levels of protection 2 3 Vaccination 4 Mobility Social distancing Mask wearing Life COVID-19 mortality rate by Vitality status >90% effective in reducing death https://sacoronavirus.co.za/latest-vaccine-statistics/ Unknown Changing New variants are emerging constantly, e.g. C1.2. Awaiting data but probably lower risk than Delta Significant additional protection against severe disease and death -- 8 of 81 -- 9 Data supports efficacy of vaccination against COVID-19 1 Surveillance of influenza and other respiratory viruses in the UK Winter 2019 to 2020 2 Sisonke and SAMRC, test negative refreshed to 17 July 3 Test negative study refreshed to 15 August COVID-19 vaccination reduces risk of mortality relative to influenza1 Deaths per million of the population 208 Without a COVID vaccine Influenza With a COVID vaccine 8-10x impact of flu 28% reduction if vaccinated Confirmed infection Discovery Health data on vaccine effectiveness* Vaccine is >90% effective in reducing death Admission High care/ICU Death J & J 28+ days since vaccination2 Pfizer 7+ days - second dose3 *Excludes data on members vaccinated in the public sector. To be submitted for peer review and publication 1 813 150 0 10 20 30 40 50 60 70 80 90 100 J & J Pfizer 0 10 20 30 40 50 60 70 80 90 100 J & J Pfizer 0 10 20 30 40 50 60 70 80 90 100 J & J Pfizer 0 10 20 30 40 50 60 70 80 90 100 J & J Pfizer Reduction in risk relative to unvaccinated 50-80% Reduction in risk relative to unvaccinated 70-85% Reduction in risk relative to unvaccinated 70-90% Reduction in risk relative to unvaccinated >90% -- 9 of 81 -- 10 0 2 4 6 8 10 12 14 16 18 5-Jul 19 Jul 2 Aug 16 Aug 30 Aug 13 Sep 27 Sep 11 Oct 25 Oct 08 Nov 22 Nov 06 Dec Millions J&J Pfizer 0.0 0.5 1.0 1.5 2.0 2.5 5-Jul 19-Jul 2-Aug 16-Aug 30-Aug 13-Sep 27-Sep 11-Oct 25-Oct 8-Nov Millions J&J Pfizer first Pfizer second Demand generation is paramount to ensure capacity utilisation Vaccination Profile (doses) Slow take up in younger cohorts First dose ramp up per age group Discovery clients vaccinated* by age band Stock Profile Delivery schedule Daily doses based on a 6 day week Underutilised capacity xx Millions Supply Demand Constraints 168 154 231 212 185 204 350 - 370 140 250 355 325 320 315 275 0% 10% 20% 30% 40% 50% 60% 70% 80% 10-May 24-May 7-Jun 21-Jun 5-Jul 19-Jul 2-Aug 16-Aug 60+ 50-59 35-49 18-34 9 weeks 6 weeks 4 weeks 5 weeks 55% 40% 22% 4% 4 weeks 7 weeks Millions 0% 10% 20% 30% 40% 50% 60% 70% 80% 10-May 24-May 7-Jun 21-Jun 5-Jul 19-Jul 2-Aug 16-Aug 30-Aug 76% 65% 54% 25% >101k Outbound calls >19m Emails and SMSes sent *partial or fully -- 10 of 81 -- 11 - 200 400 600 800 1,000 1,200 1,400 1,600 1,800 2,000 20200201 20200219 20200308 20200326 20200413 20200501 20200519 20200606 20200624 20200712 20200730 20200817 20200904 20200922 20201010 20201028 20201115 20201203 20201221 20210108 20210126 20210213 20210303 20210321 20210408 20210426 20210514 20210601 20210619 20210707 20210725 20210812 20210830 20210917 20211005 20211023 20211110 20211128 20211216 20220103 20220121 20220208 20220226 20220316 20220403 20220421 20220509 20220527 20220614 20220702 20220720 20220807 20220825 20220912 20220930 20221018 20221105 20221123 20221211 20221229 4th wave depends on the R factor and proportion of people infected. Given the high infection rate, together with vaccines, higher 4th wave mortality would require very high assumed R1 The likelihood of a mortality impact in the 4th wave is low National incremental deaths scenarios At least partially vaccinated Fully vaccinated over age 60 Total lives Members over age 60 Health 51.2% 76.2% 64.4% Individual Life2 61.8% 76.6% 62.1% Group Life2 51.1% 78.4% 62.8% Encouraging Discovery population to get vaccinated 1 R assumption peaks at 1.5 in Medium, 1.6 in High and 2.0 in New variants 2 Sum assured weighted 90% excess deaths Low Medium High No Vaccine Total (k) 235 240 245 265 Aiming to vaccinate >80% 60+yrs members by end September >80% whole book by end 2021 100% take-up of the 2nd dose where applicable Actual % vaccinated FY22 FY21 FY20 -- 11 of 81 -- 12 Unprecedented health tragedy; with the fourth wave posing further risk COVID-19 vaccines are effective and safe Public health imperative Issue is no longer one of limited access to vaccines, but one of hesitancy Supported by a legal obligation to protect and safeguard all employees from all potential risks 1 2 3 4 5 Intent to implement mandatory vaccination policy from 1 January 2022 >30k >220k excess deaths since May 2020 >14k client deaths 20 employee deaths Lives saved if >60% population vaccinated over coming months 50-80% lower risk of infection 70-85% lower risk of hospitalisation 90-95% lower risk of death Compared to those who are unvaccinated: <1 in 20 Discovery members showed any signs of side-effects 50-80% lower transmission risk for vaccinated individuals Slow take up in younger cohorts 100% Target vaccination take-up Clear moral and social obligation as informed by our Core Purpose to make people healthier and to enhance and protect their lives >890k members of Discovery Health administered schemes vaccinated 300k individuals outside of this DSY has helped vaccinate: 6 -- 12 of 81 -- 13 30-Jun-20 30-Jun-21 30-Jun-20 30-Jun-21 -3000 -2500 -2000 -1500 -1000 -500 0 500 Individual Life Group Life New individual Life provisions net of margins AURR Group Life FY21 earnings impact FY20 earnings impact Increasing the COVID-19 provision in SA, and releasing in the UK Provisions more than sufficient due to UK’s effective and early vaccine campaign Provisions and positive lapse experience in Individual Life more than sufficient to cover in- period COVID-19 claims, net loss recorded in Group Life Discovery Life Vitality Life R2 160m R2 693m COVID-19 provisions Income statement impact (R2 448m) In period COVID-19 impact net of provisions and lapse gains £28.8m £5.4m R2 800m Life provisions across the Group R2 448m DL earnings impact for period under review COVID-19 provisions (R1 058m) *Claims provision release of R1175m + lapse gain of R831m minus identified COVID-19 claims of R1673m * -- 13 of 81 -- Resilient operating performance 2 -- 14 of 81 -- 15 Health 3 423 +7% 6 453 +6%* Life 1 341 -55% 2 264 -1% Invest 1 084 +31% 2 737 +3% Insure 250 +2% 1 287 +18% Bank (1 094) -7% >81 000 New-to-Bank clients +86% Vitality Health 953 +15% 1 367 +10% Vitality Life 644 +337% 1 141 -9% Vitality Group 417 +35% 1 270 +12% Ping An Health 411 +126% 3 938 +10% Other New (978) -7% 2 114 +156% +11% New business R22.6bn +7% Operating profit R6.5bn Continued operational excellence, growth in DHMS lives and providing significant support to members and society Significant negative COVID-19 mortality impact but delivering positive actuarial variances through excellent retention experience and maintaining financial strength Strong earnings growth, retention and excellent investment returns for customers. New business growth curtailed by lower guaranteed plan sales Strong new business growth and robust underwriting performance with earnings impacted by lower investment yields Robust operating performance driven by continued good retention. Careful management of delay of elective healthcare in the COVID-19 environment Strong recovery, strengthening of underlying actuarial basis and successful execution of management plan. New business slowed with lockdowns and the focus on quality business Robust growth due to increasing integration and traction with existing partners and accelerating roll-out to new markets and adjacencies Focus on profit quality and scale through both distribution channels and product diversification. Capital injection to support long-term growth Strong high-quality client and deposit growth while deliberately pursuing a prudent, quality-focused credit strategy Lower spend combined with excellent growth in new business API *Including new closed schemes Resilient performance -- 15 of 81 -- 16 - 5,000 10,000 15,000 20,000 25,000 2017 2018 2019 2020 2021 Health Life Invest Vitality VH VL Emerging New Operating profit and New business Operating profit Before SA COVID-19 impact - 2,000 4,000 6,000 8,000 10,000 2017 2018 2019 2020 2021 Operating profit COVID-19 impact +25% +7% SA mortality New business Including new closed schemes and Vitality Group Emerging and New growing strongly 38% 11% - 5,000 10,000 15,000 20,000 25,000 2017 2018 2019 2020 2021 +11% +5% +14% +10% Recovered from 2020 COVID-19 impact, 8% CAGR on 2019 Emerging and New Emerging and New Emerging and New Established -- 16 of 81 -- 17 Resilient operating performance, actuarial dynamics within expectation Lapses – vs expected Claims – vs expected Paid up Withdrawals Health Life Invest Insure Health Life 0% 50% 100% 150% Jul Sep Nov Jan Mar May 0% 50% 100% 150% Jul Sep Nov Jan Mar May 0% 50% 100% 150% Jul Sep Nov Jan Mar May 0% 50% 100% 150% Jul Sep Nov Jan Mar May 0% 50% 100% 150% Jul Sep Nov Jan Mar May 0% 50% 100% 150% Jul Sep Nov Jan Mar May 0% 50% 100% 150% Jul Sep Nov Jan Mar May 0% 50% 100% 150% Jul Sep Nov Jan Mar May 98% 91% FY AvE 76% 100%1 76% 82% 92% 98% 88% 84% 72% 102%2 0% 50% 100% 150% Jul Sep Nov Jan Mar May 0% 50% 100% 150% Jul Sep Nov Jan Mar May 0% 50% 100% 150% Jul Sep Nov Jan Mar May 0% 50% 100% 150% Jul Sep Nov Jan Mar May 1 Individual Life, excluding identified COVID-19 claims 2 Excluding identified COVID-19 claims -- 17 of 81 -- 18 Reported profit for period affected by foreign exchange movements Rm 12 months ended Jun 2021 12 months ended Jun 2020 % Normalised profit from operations 6,494 6,069 7% Economic assumptions adjustment DL -411 -3,635 Economic assumptions adjustment VL -108 -1,195 Finance charges excl. 1DP finance lease -1,291 -1,218 Unrealised (losses)/gains on foreign exchange contracts not designated as a hedge -304 263 Foreign exchange (losses)/gains -389 578 Deferral fees related to Prudential Book transfer -187 -71 Investment income and fair value remeasurements 83 338 Dilution gains from equity accounted investments 554 3 Other -234 -609 Profit before tax 4,207 523 704% Tax -987 -347 Profit attributable to preference and minority shareholders -63 -79 Profit attributable to equity holders 3,157 97 3155% Headline adjusting items -171 199 Headline earnings 2,986 296 909% Economic assumptions adjustment (DL and VL) 383 3,584 Other normalisation adjustments 37 -133 Normalised headline earnings 3,406 3,747 -9% Forex exchange (gains)/losses net tax 305 -424 Normalised headline earnings excl forex impact 3,711 3,323 +12% Due to the continued uncertainty and potentially volatile economic environment caused by the COVID-19 pandemic, the Discovery Board has decided to retain its prior stated position during the pandemic and has decided not to declare an ordinary final dividend for the period ended 30 June 2021. The reintroduction of an ordinary dividend will be considered on an ongoing basis 1 2 3 1 2 3 Stabilisation of long term interest rates in SA and the UK resulted in materially lower economic basis changes than the prior year, R4.3bn swing Mark-to-market foreign currency losses arising from a recovery of the Rand during the reporting year compared to a gain in the previous financial year, R1.5bn swing Unrealised gain from the transaction in which Cambridge Mobile Telematics (CMT) acquired TrueMotion -- 18 of 81 -- Capital strength and liquidity 3 -- 19 of 81 -- 20 Group is well capitalised and highly liquid Jun 20 Cover Jun 21 Cover Life 1.8x 1.8x Insure 1.8x 1.8x VH 1.7x 1.6x VL 2.0x 2.4x Bank1 1.6x 1.4x PAH 1.9x 2.3x 1 Capital Adequacy Ratio 2 Considers SA Liquidity and liquid excess assets for Discovery Life, Discovery Insure, VitalityHealth, VitalityLife and Discovery Bank 3 SA cash + undrawn committed facilities SA Liquidity3 , R millions FLR R millions Liquid excess assets above minimum regulatory capital requirements Strongly capitalised FLR is within target Highly liquid across the Group2 Sufficient liquidity at the centre - 5,000 10,000 15,000 FY18 FY19 FY20 FY21 DHMS solvency 36.9% 15% 17% 19% 21% 23% 25% 27% 29% FY17 FY18 FY19 FY20 FY21 28% 25.7% - 500 1,000 1,500 2,000 FY18 FY19 FY20 FY21 -- 20 of 81 -- 21 Cash generated Cash used Funding New business Net cash flow1 New businesses Net cash generated from in-force business R13.0bn Tax and finance costs R2.6bn R7.9bn R1.3bn R1.8bn Cash generation positive prior to COVID-19 R13.0bnCash generated from in-force 1 Movement in shareholder free cash R14.3bn Cash used net of funding (R1.3bn) Net cash flow Reinsurers Debt R1.0bn Vitality Life Vitality Health Discovery Life and Invest Discovery Health Gross Life COVID-19 claims R3.0bn -- 21 of 81 -- 22 Opening EV Value of new business Unwind of risk discount rate Non-Economic Experience Variances and Methodology & Assumption Changes COVID-19 impact Operational EV Economic Experience Variances and Methodology & Assumption Changes Forex Other Closing EV 4.6% Annualised ROEV 11% excluding COVID-19, forex and economic changes Group Embedded Value R74 645m R78 608m R70 834m ~25% total adjusted revenue1 attributable to Emerging and New Group revenue 1 Including 25% Ping An Health earned premium and Bank NII and NIR and excluding insurance premium revenue from the Invest segments - 10,000 20,000 30,000 40,000 50,000 60,000 70,000 2017 2018 2019 2020 2021 Total Group Group excl Emerging and New Rm -- 22 of 81 -- Three dimensions of growth 4 -- 23 of 81 -- 24 The rise of digital Ways of work Ecommerce Telemedicine Contactless ESG Moral money Climate change Social movements Mortality Morbidity Driving Investing Banking Significant increase in ecosystem strategies globally Insurtech and ecosystem strategies are increasing Many have invested substantially into health ecosystems2 76% p.a. 1 CB Insights 2 McKinsey 2021 77x (of 11/20) 8x (of 2/20) 16x (of 4/20) 20x (of 5/20) 40x (of 10/20) Sample of 20 large insurers globally have strategically invested into various ecosystems over the last few years, with health being a prominent theme (32% of investments) Blurring of boundaries in these three trends Number of mentions of ecosystems in leading European insurers and medtech providers2 xx Health funding in EUR m Core business Funded health start-ups Funded start-ups from other ecosystems (mobility, housing, education, B2B services) Record quarter for insurtech investment activity1 - 500 1,000 1,500 2,000 2,500 3,000 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2016 2017 2018 2019 2020 2021 USD m -- 24 of 81 -- 25 Evolving the business model to an ecosystem Institution Platform Ecosystem Bank Motor Invest Life Health Institution Platform Composite “Make people healthier” -- 25 of 81 -- 26 Three dimensions of growth 1 2 3 Geographic growth Platform-led growth Organic growth Expand the Vitality global insurtech platform Create superior institutions Grow globally with the ability to repeat and scale Grow organically Build new businesses that scale Achieve superior returns on capital ESTABLISHED EMERGING NEW Institution Platform -- 26 of 81 -- 27 Emerging businesses are scaling rapidly Organic growth R1.1bn R2.0bn R9.9bn (-1% to R7.5bn) ESTABLISHED EMERGING NEW % in New*: 19% 24% 14% 7% 5% - 5,000 10,000 2017 2018 2019 2020 2021 After COVID-19 impact COVID-19 impact -500 - 500 1,000 1,500 2017 2018 2019 2020 2021 -3,000 -2,000 -1,000 - 2017 2018 2019 2020 2021 +46% +74% +94% +15% +0% +3% +13% -1% -13% *Pre-COVID-19 impacts New definition is as % of core (Established and Emerging) instead of total operating profit Operating profit 23% 31% 17% 8% 5% New Old definition Established businesses remain robust SA mortality +46% to +15% to Turning point in the spend on New businesses 1 -- 27 of 81 -- 28 Emerging businesses are growing rapidly and achieving good returns 2017 2018 2019 2020 2021 +2% Insure Vitality Group Ping An Health 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 ROE ROE ROE 10.4% -200 - 200 400 600 800 1,000 1,200 2017 2018 2019 2020 2021 Operating profit Operating profit Operating profit Strong growth from Emerging Operating profit Rm 14.5%ROE Normalised RoE in local currency, and only considers Emerging parts of business – Insure excludes CMT and VG excludes new initiatives -- 28 of 81 -- 29 New businesses are seeing considerable traction Bank Vitality1 Vitality Invest DBI Umbrella Funds 0 200 400 600 800 1,000 1,200 1,400 FY19 FY20 FY21 Millions 0 5 10 15 20 25 30 35 40 FY19 FY20 FY21 +86%New-to-Bank Clients +75%New business (£m) New markets launched FY20-FY21 +52%New business +290%New business 0 20 40 60 80 100 120 140 160 180 200 FY19 FY20 FY21 Millions - 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 FY19 FY20 FY21 -- 29 of 81 -- 30 Geographic growth +6% to R7.1bn (-17% to R4.7bn) Operating profit Operating profit 3,000 4,000 5,000 6,000 7,000 8,000 2017 2018 2019 2020 2021 After COVID-19 impact COVID-19 impact +6% +1% -5% +9% -17% -15% SA mortality - 500 1,000 1,500 2,000 2017 2018 2019 2020 2021 +334% -61% +12% +84% 2 DBI Umbrella Funds VG New -- 30 of 81 -- 31 Platform-led growth ENHANCED INSURANCE VALUE CHAIN TECHNOLOGY AND ANALYTICS LAYER DATA LAYER BEHAVIOURAL LAYER INCENTIVE LAYER PRODUCT LAYER PREDICT VALUE INTERVENE Attract Price Change Behaviour Retain BEHAVIOURAL DESIGN Nudge theory Loss Aversion GLOBAL INTEGRATED PARTNERS Resonance design Pre-commitment PREDICT INTERVENE FUTURE HEALTH  Next-best action model Gateway Portal GLOBAL DATA ENGINEERING HEALTH >50m Life years of behavioral linked insurance data 300k New members every month >3.5m Device tracking events a week 13bn INSURANCE PRICING Device- led Wedge funding Dynamic pricing BEHAVIOURAL VALUE MATCHING Net VIF uplift model PLATFORM ENABLEMENT MOBILE CONTENT MANAGEMENT VITALITY 1 World-class technology platform Transforms Vitality customization Enables instant multi-language launches 3 km tracked ABC pricing -- 31 of 81 -- 32 Platform seeing good engagement and growth Customer engagement 12bn Average steps per day 3.5m Workouts logged per day 4k New devices registered per day 20k Health assessments per day 600k Goals achieved per week 41m Impacted lives 30 Markets Platform income* Shared Value outcomes SA UK Market A SA UK Life Insurance Health Insurance Motor Insurance Long-term Savings Banking Actuarial value – initial selection, better retention, improved claims, lower prices, selective lapses Arrears Shared Value to customers in FY21 2,499 1,864 245 Premium discounts Cash backs Boosts R4.6bn R4.0bn +8% Revenue through the platform (Rm) *Platform income made up of Vitality membership premiums and Vitality Group revenue 2019 2020 2021 Offshore SA Blue Bronze Silver Gold and Diamond Claims ratios by status -- 32 of 81 -- 33 1 2 4 3 Manifesting as unique composites and partnerships Perfect composite model, #1 in every industry, and the Bank pivoting to growth as the composite-maker within SA Best-in-breed products across businesses and operating as a fully integrated composite business with a seamless One Vitality client journey. A successful entry into motor insurance Vitality is the world’s largest and most sophisticated behavioural platform linked to financial services Ping An Health delivers on its plan to become the leading health insurer in China with over 50m clients Discovery Insure Discovery Life Discovery Invest Discovery Bank Discovery Health Vitality Health Vitality Car Vitality Life Vitality Invest Global Network USA -- 33 of 81 -- 34 Discovery Insure Discovery Life Discovery Invest Discovery Bank Discovery Health Strong high-quality client and deposit growth while deliberately pursuing a prudent, quality-focused credit strategy -- 34 of 81 -- 35 Discovery Bank Total accounts Retail deposits Total clients Advances Spend 307k 362k J A S O N D J F M A M J Primary Secondary 505k 649k J A S O N D J F M A M J R3.1bn R8.2bn J A S O N D J F M A M J R3.6bn R3.8bn 0.00 500,000,000.00 1,000,000,000.00 1,500,000,000.00 2,000,000,000.00 2,500,000,000.00 3,000,000,000.00 3,500,000,000.00 4,000,000,000.00 J A S O N D J F M A M J R1.1bn R20.2 J A S O N D J F M A M J 362k 649k R8.2bn R3.8bn R20.2bnYTD spend -- 35 of 81 -- 36 A full-service shared-value Bank Banking ecosystem Behavioural Functionality 1 2 3 4 5 High-quality client growth Attracting deposits Growing quality advances Market-leading functionality Powerful shared-value fundamentals and currency Strategic focus areas -- 36 of 81 -- 37 1. Strong growth to ±500 average daily sales with high-quality growth Quality client growth Opportunity within DSY and non-DSY client base New-to-Bank daily sales ±500 average daily new-to-Bank sales Achieved the medium-term targets 60% 40% Bank client with DSY products Bank only DSY Bank Big 4 Top 5 Retail Banks Primary versus secondary clients Big 4 and Top 5 NIR is the client-weighted average Big 4 include Standard Bank, FNB, ABSA and Nedbank Top 5 Retail Banks include Standard Bank, FNB, ABSA, Nedbank and Capitec 9% 13% 20% 26% 32% Blue Bronze Silver Gold Diamond Current penetration Opportunity Vitality penetration 92% Primary Secondary DSY product uptake – Bank new business 198 264 353 490 0 100 200 300 400 500 600 FY21 Q1 FY21 Q2 FY21 Q3 FY21 Q4 Average NIR per client per month -- 37 of 81 -- 38 2. Deposits have continued their strong growth trajectory Deposits are sticky and diverse Consistent growth in retail deposits 38% 13% 49% Duration > 3 months < 3 months - None/Blue < 3 months - Bronze+ 5% 95% Concentration Top 10 depositors Others R3.1bn R8.2bn J A S O N D J F M A M J R8.18bn Growth of 167% from July 2020 to June 2021 vs 7% for the market -- 38 of 81 -- 39 3. Deliberate decision to pursue a prudent, quality-focused credit strategy Superior credit risk metrics Credit loss ratio Retail advances New-to-Bank credit application metrics (excl. COVID-19 overlay) 3.96% 0% 3% 6% 9% J A S O N D J F M A M J R3.6bn R3.8bn 0.00 500,000,000.00 1,000,000,000.00 1,500,000,000.00 2,000,000,000.00 2,500,000,000.00 3,000,000,000.00 3,500,000,000.00 4,000,000,000.00 J A S O N D J F M A M J Growth of 5% from July 2020 to June 2021 – above market growth of 4.5% 34% 52% 0% 50% 100% Discovery Bank Market Subprime Near prime Prime Prime plus Super prime NEW CLIENTS RISK DISTRIBUTION JAN – MAR 2021 EXISTING CLIENTS RISK DISTRIBUTION JAN – MAR 2021 17% 30% 0% 20% 40% 60% 80% 100% Discovery Bank Market 0% 5% 10% 15% 20% 25% 30% 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 FY21 Q1 FY21 Q2 FY21 Q3 FY21 Q4 Applications Approve rate -- 39 of 81 -- 40 202007 202008 202009 202010 202011 202012 202101 202102 202103 202104 202105 202106 4. Shared-value fundamentals emerging as expected with Discovery Miles as a powerful currency The Discovery Miles currency is central to the Bank’s ecosystem and the SA composite Shared-value fundamentals 94%lower arrears rate Gold and Diamond vs Blue 3.20% 1.26% 0.62% 0.18% Blue Bronze Silver Gold and Diamond 1 2 12 92 Blue* Bronze Silver Gold and Diamond 1 1 2 4 Blue Bronze Silver Gold and Diamond Indexed to Blue 9xhigher average deposits Gold and Diamond vs book average 4xgreater spend Gold and Diamond vs Blue Online and in- store Prepaid products and services Travel Transfer and convert Physical activity Drive Spend Healthy living Get up to when you spend Discovery Miles in the Vitality Mall, online and on prepaid products and services in FY2021 4.9bnearned 2.9bnspent in FY2021 Cumulative Miles earned 1 5.5 8.5 Daily average Black Friday Miles D-Day (July) Miles spend Continuous innovation New ways to earn Miles New ways to spend Miles -- 40 of 81 -- 41 5. Differentiated, market-leading functionality with a focus on digital sophistication Continued innovation Continued innovation Innovations successfully rolled out Several enhancements being rolled out in September Account origination Payments Account management Rewards Service Travel Security ?  Sign up 24/7/365 in <5 mins  Transact immediately with a Virtual Card  Apple Pay  Discovery Pay  Seamless account setup  Manage accounts and cards in-App  Live Assist  24/7/365 online  Shared-value stack: Interest rates, shopping & retail discounts  Miles more valuable than cash at a broad partner network  Discounts on local and international flights  Lounges  FastTrack “Four-Factor protection”:  Smart delays: Geo-fencing and AI account monitoring, hard daily transfer caps, distressed facial recognition Examples; not exhaustive Forex proposition Health Pay and Vitality Pay Financial Analyser Smart Vault 1 2 3 Simple account opening in under two minutes Real-time exchange rates and transactions Easily manage foreign currency allowances -- 41 of 81 -- 42 Discovery Insure Discovery Life Discovery Invest Discovery Bank Discovery Health Continued operational excellence, growth in DHMS lives and providing significant support to members and society -- 42 of 81 -- 43 Discovery Health Membership Direct manex Normalised operating profit New business >3.7m lives under administration Rm (plpm) +7% to R3 423m +3% 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015 2017 2019 2021 Non-scheme products Closed schemes DHMS 127.93 133.48 2020 2021 +6%to R6 453m -- 43 of 81 -- 44 Discovery Health Medical Scheme performance summary Value Security Growth and stability R2.2bn Contribution savings for DHMS members Delayed contribution increase DHMS Scheme A Scheme B Scheme C Scheme D Scheme E Scheme F 2021 weighted average increases 2.95% 36.9% Solvency1 AAA GCR credit rating1 >2.75m 57% market share2 lives1 5.2% lapse rate1 Debit order rejections 4% 5% 6% 7% Source: Discovery Health Medical Scheme and the Council of Medical Schemes 1 As at 31 December 2020 2 Based on beneficiaries, according to the Council for Medical Schemes Quarterly Report for the period ended 30 September 2020 2002 2004 2006 2008 2010 2012 2014 2016 2018 2020 R27.5bn reserves1 Reserve build-up -- 44 of 81 -- 45 0 100 200 300 400 500 600 - 0.4 0.8 1.2 1.6 2.0 Mar - 20 May - 20 Jul - 20 Sep - 20 Nov - 20 Jan - 21 Mar - 21 May - 21 Jul - 21 OH Claims GP Consults OTC Meds Pre-COVID levels Utilisation patterns, which are the main driver of medical inflation, have been disrupted Wave 1 peak Wave 2 and 3 peaks COVID-19 admissions IN-HOSPITAL CARE OUT-OF- HOSPITAL CARE COVID-19 ADMISSIONS 1 2 3 - 1,000 2,000 3,000 Pre-COVID levels Total hospital admissions -- 45 of 81 -- 46 Emerging non-COVID-19 utilisation patterns over the period 2 3 IN-HOSPITAL CARE OUT-OF-HOSPITAL CARE Reduced across the board, with a shift from large acute hospitals to smaller day surgery type facilities Starting to increase, with increased care at home and changes in health-seeking behaviour Decline in preventative and screening care Move to care outside large hospitals Decline in discretionary medical admissions Decline in maternity- related utilisation Spike in pathology claims Depression registrations -20% Diabetes management -27% Breast cancer screening -55% Cardiac catheterisation Endoscopies Tonsillectomy and adenoid Admissions Admissions Claimants Admissions Spinal medical procedures Proportion of admissions occurring in a day clinic 2016 2017 2018 2019 2020 +56% 0 100,000,000 200,000,000 300,000,000 400,000,000 500,000,000 600,000,000 Jan Feb Mar Apr May Jun Jul Aug 2019 2020 2021 % Pre-38 week births Admissions average LOS Neonatal admissions NICU admissions -- 46 of 81 -- 47 Accelerated digitisation of the healthcare system | DH ideally positioned Discovery Health has a fully integrated digital healthcare platform Global expansion of digital healthcare % of US consumers using telehealth Growth in provider remote consults 2019 to 2020 ~ 50 – 175 x 11% 46% 2019 2020 Evidenced by telemedicine use Platform achieved scale through vaccination journey 129,640 269,907 1,118,689 2019: DrConnect (Pre-COVID) 2020: DrConnect (COVID) 2021: Connected Care (Since 1 Apr-21) Member logins Ecosystem has a comprehensive patient record, and connects the communities of doctors, members and case managers across a common platform with integration to various parts of the medical system DH is already deploying AI and digitisation for homecare and enhanced quality 1.01m logins Connected Care Vaccine Navigator 3.68m logins Detailed medical examinations and advanced virtual consultations 24/7 doctor support End-to-end digital experience Convergence of clinical and data insights to offer high quality care at home -- 47 of 81 -- 48 Discovery Insure Discovery Life Discovery Invest Discovery Bank Discovery Health Significant negative COVID-19 mortality impact but delivering excellent retention experience and maintaining financial strength -- 48 of 81 -- 49 Discovery Life Strong capital and liquidity position New business API Normalised operating profit 2017 2018 2019 2020 2021 COVID-19 impact -55%to R1 341m -6% Before COVID-19 impact -1%to R2 264m 2017 2018 2019 2020 2021 182% 183% 2020 2021 4,149 4,420 2020 2021 125% SCR target FY21 net cash outflow 7x SCR coverage Liquidity coverage -- 49 of 81 -- 50 Discovery Life gross COVID-19 claims Total (Rm) - 100 200 300 400 500 600 700 800 Mar-20 Apr-20 May-20 Jun-20 Jul-20 Aug-20 Sep-20 Oct-20 Nov-20 Dec-20 Jan-21 Feb-21 Mar-21 Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21 Oct-21 Nov-21 Dec-21 Jan-22 Feb-22 Mar-22 Apr-22 May-22 Jun-22 Actual Provision Scenario FY 2021 FY 2022* Wave 1 = R538m Wave 2 = R1 871m Wave 3 to 30 June 2021 = R689m FY 2020 Provision Scenario  Prudent best estimate  60% vaccination by November Monthly Death Outgo (R’m) Individual (Rm) 31 Group (Rm) 24 Total (Rm) 55 Individual (Rm) 2 207 Group (Rm) 835 Total (Rm) 3 042 Individual (Rm) 2 253 Group (Rm) 866 Total (Rm) 3 119 Actual to Aug 21 (Rm) 2 156 4 491 1 725 6 216 -- 50 of 81 -- 51 Premiums and fees Claims Reinsurance Existing financing cashflows Operational costs Cashflows from existing NB strain Net Life and Invest cashflow after FinRe Robust embedded value growth driven by positive operating variances with continued exceptional persistency experience Maintained strong positive operating variances 2020 2021 Embedded Value +10% 401 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 Non-economic EV Variances (Rm) 421 411 2020 2021 5.8% 5.7% 2020 2021 VNB VNB Margin 31.8bn 34.8bn Excluding COVID-19 7.1% 8.0% 519 586 VNB impacted by lower volumes and COVID-19 provision strengthening Cashflow impacted by COVID-19 claims Rm Gross COVID-19 claims R3bn Overall COVID-19 impact on cashflow of cR1.5bn net of all risk and financial reinsurance -633 2 196 15 694 -- 51 of 81 -- 52 Looking ahead and optimising Life insurance post the 3rd wave 1 Well capitalised and highly liquid 2 Highly engaged and vaccinated client base 3 Products adjusted for COVID-19 Supported strong back book cash generation: >R15bn premium income 182% 183% 2020 2021 4,149 4,420 2020 2021 125% SCR target FY21 net cash outflow 7x SCR coverage Liquidity coverage Back book cash generation Actively driving vaccinations Differentiate between vaccinated/unvaccinated lives Product features VACCINATION MAX OFFER Understanding relative COVID-19 risk across age bands 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 Base mortality rate at age 45 None Blue Bronze Silver Gold Diamond off Bronze 38% High Vitality engagement % Life book vaccinated to date Count basis Sum assured basis % of total book 57% 62% % of 60+ years 73% 77% % of 50+ years 69% 71% % of 35+ years 63% 66% -- 52 of 81 -- 53 Discovery Insure Discovery Life Discovery Invest Discovery Bank Discovery Health Strong earnings growth, retention and excellent investment returns for customers. New business growth curtailed by lower guaranteed plan sales -- 53 of 81 -- 54 New business +3% Rm Assets under administration +18% Rbn 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 +16% +31% 2019 2020 2021 Discovery Invest to R2 737m 2017 2018 2019 2020 2021 to R117bn Non-recurring profit contributions, include release of COVID lapse provisions and GILF matching profits Normalised operating profit +31% Rm Lapse rates -13% to R1 084m -- 54 of 81 -- 55 Key highlights over the past financial year 12% increase in linked product sales More profitable business sold over the last financial year, with offshore sales up 81% Linked products as proportion of new business 57% 68% 2020 2021 Strong investment performance Shared value continues to drive good outcomes +3 years Average investment term +338% In extra contributions -22% Income withdrawal level One year Three year Five years Discovery Dynamic Asset Optimisers Conservative Q1 Q1 Q1 Moderate Q2 Q1 Q1 Aggressive Q1 Q1 Q1 Discovery Balanced Funds Balanced Q2 Q2 Q2 Moderate Balanced Q2 Q2 Q1 Cautious Balanced Q2 Q1 Q1 Multi-asset 26% Flexible Property 22% Local single-asset* Equity Global equity* 34% 16% Equity Feeder Value *Growth over one year -- 55 of 81 -- 56 Discovery Insure Discovery Life Discovery Invest Discovery Bank Discovery Health Strong top-line growth and robust underwriting performance with earnings impacted by lower investment yields -- 56 of 81 -- 57 Discovery Insure Personal Lines only. Assumes 6% in GWP market growth since 2018 *Personal Lines only Normalised operating profit +2% New business +18% Gross written premium +15% Market share in GWP 7% Operating margin* 6% to R250m (excl. Commercial) to R4 205* to R1 287m* 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 -- 57 of 81 -- 58 Analysing the profit dynamics CMT profits are net of SA costs COVID-19 had an impact on driving, claims and profit in FY21 2020 2021 0 50 100 J F M A M J J A S O N D J F M A M J J Infections (k) 100% 19% 60% 0% 40% 80% 120% J F M A M J J A S O N D J F M A M J J Driving activity 2020 2021 Infections Driving Activity v regular levels R56m additional actual profit R114m additional profit R58m additional rewards given - = (R59m in FY20) Normalised Operating Profit CMT Investment Income Operating Profit Profit composition reveals a strong increase in core operating profit (Rm) FY20 FY21 Normalised Operating Profit CMT Investment Income Operating Profit 246 -13 -114 119 Covid related 250 -3 -84 163 Covid related -- 58 of 81 -- 59 The Vitality Drive model improves each year 28% proportion of book shifted over 4 years to Silver and up 2017 2018 2019 2020 2021 Blue Bronze Silver Gold Gold Blue Bronze Silver Status correlations well established Gold Blue Bronze Silver Loss ratio by status Lapse ratio by status Improved status distribution leverages these dynamics -34% This manifests iteratively in an improving claims ratio -65% 60% 56% 55% 51% 52% 2017 2018 2019 2020 2021 Motor claims ratio Total claims ratio 56% 55% 52% 44% 47% 2017 2018 2019 2020 2021 -- 59 of 81 -- 60 Vitality Health Vitality Car Vitality Life Vitality Invest -- 60 of 81 -- 61 UK Composite GBP millions GBP millions GBP millions Vitality Health, Vitality Life, Vitality Invest and Other 1 Vitality Health and Vitality Life only Earned premiums1 +5% Lives covered +8% to £827.4m to 1.4m lives Normalised operating profit +844% New business +7% to £68.5m to £156.7m Vitality Health Vitality Car Vitality Life Vitality Invest Best-in-breed products across businesses and operating as a fully integrated composite business with a seamless One Vitality client journey. A successful entry into motor insurance -- 61 of 81 -- 62 Robust operating performance driven by continued good retention. Careful management of delay of elective healthcare in the COVID-19 environment Vitality Health Vitality Car Vitality Life Vitality Invest -- 62 of 81 -- 63 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 Vitality Health GBP millions GBP millions GBP millions Earned premiums +4%to £515.6m Normalised operating profit +9% New business +5%to £46.0m to £65.9m 2017 2018 2019 2020 2021 Lives covered +6%to 723k lives -- 63 of 81 -- 64 Operational performance continues to be outstanding and business well prepared for the coming period Stronger and better retention Low loss ratios, but returning to prior levels 100 68 58 59 54 2017 2018 2019 2020 2021 Lapse Rate Actual v Pre-COVID expected loss ratio has precipitated a surplus 98 106 76 3233 43 67 74 88848783 72 8482 93 99 105 Jan Mar May Jul Sep Nov Jan Mar May 2020 2021 FY21 Pre-COVID expectation = 100 36.1 14.2 39.7 2020 2021 Rescheduled FinRe UPR Short-term increase in claims within contract boundary Providing for longer- term increases: 1. Long Covid 2. Long term increase in claims e.g. cancer increases 3. Catch-up experience- based premium increases Good cash generation Cash generated from inforce Write new business Invest in project initiatives Net cash generated £128m £56m Provided for uncertain future claims through UPR and rescheduled FinRe £m -- 64 of 81 -- 65 Strong recovery, strengthening of underlying actuarial basis and successful execution of management plan. New business slowed with lockdowns and the focus on quality business Vitality Health Vitality Car Vitality Life Vitality Invest -- 65 of 81 -- 66 Vitality Life Earned premiums +8% Lives covered +10% to £311.8m Normalised operating profit +325% New business -14% to £31.0m to 680k lives to £55.0m 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 GBP millions GBP millions GBP millions -- 66 of 81 -- 67 Expected operating profit Experience variances (excl. COVID-19) COVID-19 claims and lapse variances COVID-19 provision strengthening Basis and model strengthening variances Normalised operating profit £30m £11.9m £2m £25.8m £31m £16.9m Favourable lapse and COVID-19 experience drove strong profit, but offset by new business shortfall and assumption changes Operating profit recon Addressed the 10 point plan -- 67 of 81 -- 68 -- 68 of 81 -- 69 Focus on profit quality and scale through both distribution channels and product diversification. Capital injection to support long-term growth -- 69 of 81 -- 70 Ping An Health 1 100% of PAH Written premium1 PAH’s operating results pre-tax to R40.6bn New business1 Discovery’s operating result after tax to R15.8bn to R2.9bn (DSY’s share is R727m) to R411m 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 -- 70 of 81 -- 71 The quality of the book and profits have improved Revenue growth surged in H2 20, growth moderating in FY21 Written premiums RMB Focused on quality, as seen by highest margins in industry Net margin post tax, Jan - Dec 20 Renewal rates continue to increase and COR is reducing Renewal rates - 2 4 6 8 10 12 H1 FY17 H2 FY17 H1 FY18 H2 FY18 H1 FY19 H2 FY19 H1 FY20 H2 FY20 H1 FY21 H2 FY21 Billions +58% +20% Prior period YTD 2021 7% absolute reduction Source: publicly available financial statements Company Margin PING AN HEALTH INSURANCE COMPANY OF CHINA, LTD 5.40% KUNLUN HEALTH INSURANCE CO LTD 2.70% CPIC HEALTH 2.30% PICC HEALTH INSURANCE COMPANY LIMITED 0.10% FOSUN UNITED HEALTH INSURANCE COMPANY LTD -3.40% RUIHUA HEALTH ASSURANCE CORPORATION -28.90% Combined operating ratio 31-Dec-19 30-Jun-20 31-Dec-20 30-Jun-21 Target -- 71 of 81 -- 72 Continue to pursue scale through diversified distribution channels and products Increasing digital presence to unlock the online market Ping An Good Doctor App Le Jian Kang WeChat mini-program Home page Insurance Shop Health Q&A My profile Urology Paediatrics Dermatology Internal medicine TCM Diabetes Fertility Urinary Male health Medical services Cumulative services Earn gold status Quick Inquiry TCM Specialist Expert Doctor Medication Cloud farm Video Consult Medical examinationInsurance Health check-up Access to *400m users *As at June 2021 Integrated products Integrated services New business split by channel 0% 20% 40% 60% 80% 100% Jun-20 Jun-21 Ping An Life Broker and direct sales Cross Sales with PAG SuiShenYi online agency Online and Ping An App 24% 37% -- 72 of 81 -- 73 China’s market and strong economic growth trajectory provide an excellent long-term opportunity Policies emphasise developing healthcare and private health insurance supported by mature regulations Continued growth in healthcare expenditure, increased participation from private health insurance (RMB Trillion) ~USD 2.4trn 6 16 2019 2030 Public sector subsidised healthcare providers 2019 Private sector healthcare providers 2030 2.7x 14th five-year plan provides support in four main areas (2020-2025): Social development: Promote development of private health insurance Digitisation: Develop AI healthcare capability, online hospitals & digitise health International Collaboration: Attract foreign investment and technology in medicine, telecom, internet and education Healthy China 2030 target: Increase the number of people exercising CBIRC formed in 2018 to combine and strengthen financial supervision of insurance and banking sectors CBIRC - China Banking and Insurance Regulatory Commission Recent regulatory developments in education, technology and online pharmacy sectors, to align with policy goals Education & housing regulation address low birth rate Technology sector regulation change address anti-competitive practices, consumer protection and prudent capital requirements Online pharmacy regulations address online prescription drug safety -- 73 of 81 -- 74 PAH requires additional capital to support business growth and product diversification Total capital injection for PAH to develop additional capabilities and fund new business growth Capital requirement driven by 2 factors PAH growth imperatives along with 200% solvency requirement Change in solvency rules 70% 30% Cumulative new business portion of 20 year product Sep-20 Oct-20 Nov-20 Dec-20 Jan-21 Feb-21 Mar-21 Apr-21 May-21 Jun-21 32% PAH’s projected solvency ratio reduces without a capital injection, due to sales of more capital-intensive 20-year product • Strong market demand for renewal guarantee • Premium increase flexibility for PAH • More sustainable and profitable product • Lower average commission over term • More capital-intensive • Higher upfront commission Chinese C-ROSS Phase II regulations implemented in 2021 aim to strengthen the effectiveness of insurance regulatory system New requirements increase minimum capital requirements for insurance, market, credit and other quantitative risk factors -- 74 of 81 -- 75 USA Strong growth due to increasing integration and traction with existing partners and accelerating roll- out to new markets and adjacencies -- 75 of 81 -- 76 Vitality Group All numbers exclude new VG initiatives, i.e. myOwn and Vitality 1 Excludes services related to system implementation and other cost recoveries and rewards Revenue1 Operating result to $82.4m R1.3bn Integrated API by insurance partners Insurance and franchise partners membership to $1.3bn R19.9bn to $27.1m R417m to 2.4m 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 Insurance partners Vitality USA 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 +27% -- 76 of 81 -- 77 -35%* -35% Engagement Lapses Claims Up-sales Latent value Market A Market B Market C Market D Attachment rates % of members earned a point Deepened adoption of SVI model has been transformational for our partners 74% 58% 72% 54% 40% 45% 75% 80% Bronze Silver Gold & Platinum Non-Vitality -60% -79% -18% +73% +40% -10%* -40% +111% +98% -18%* *Pricing assumption in lieu of credible experience -- 77 of 81 -- 78 Broadening reach and scale through a repeatable framework Fully remote implementation period to launch 2-version launch with increased functionality Accelerated roll-out despite COVID Enabled by unified repeatability strategy lives 2017 2018 2019 2020 2021 -- 78 of 81 -- 79 Shared value health insurance approach TECHNOLOGY LAYER DATA LAYER BEHAVIOURAL LAYER INCENTIVE LAYER PRICING LAYER Comprehensive Digital Health Ecosystem The platform allows an expansion from 1 ecosystem to 3 -- 79 of 81 -- 80 Forward-looking focus areas Capital strength and liquidity remain a focus Injecting capital into Ping An Health to support business growth and product diversification Implement employee vaccine mandate, structural and pricing changes to products for our customers and play a central role in state-led COVID-19 response Create unique shared-value composites that offer superior value 1 Navigating COVID-19 2 Capital strength and liquidity 3 Actively pursue the three dimensions of growth 4 Execute on the four strategic strands Grow businesses organically, scale businesses offshore and expand the Vitality global insurtech platform -- 80 of 81 -- Discovery Limited Copyright 2021 Discovery Ltd is the licensed controlling company of the designated Discovery Insurance Group. Registration number: 1999/007789/06. Companies in the Group are licensed insurers and authorised financial services providers. -- 81 of 81 --